Table 1.
T cell-depleted and unmanipulated haploidentical stem cell transplantation
| Centers (year) | Disease | No. of pts | Conditioning | GVHD prophylaxis | Cell dose 106/kg | TCD methods | Graft failure | Acute GVHD | Chronic GVHD | TRM | Relapse | DFS | |
| CD34 | CD3 | ||||||||||||
| T-cell depleted | |||||||||||||
| Perugia, Italy 1994[16] |
AML/ALL/CML | 36 | TBI/TT/CY/ATG | Extensive TCD | 10.8 | 0.22 | Lectin-based+E-rosette | 1/17 | 1/16 | 0/9 | 9/17 | 2/17 | 6/17 |
| USC, USA 1997[12] |
AML/ALL | 72 | TBI/VP16/Ara-C/CY/ATG | Partial TCD CSP, MP, ATG |
1.36 | 0.075 | Ex vivo TCD with T10B9 | 2% | 16% | 35% | 65.3% | 32% | 2-year OS 55% for SR 27% for HR |
| Perugia, Italy 1998[17] |
AML ALL |
44 | TBI/TT/F/ATG | Extensive TCD | 10.5 | 0.02 | Ex vivo CD34 selection | 5% | 0 | 0 | 40% | 13% 63% |
36% 17% |
| Boston, USA 1999[40] |
AML/ALL/NHL/others | 12 | TBI/Ara-c/CY | CTLA4-Ig, CSP+MTX | 2.2 | 28 | CTLA4-Ig, | 1/11 | 3/11 | 1/11 | 7/12 | 1/12 | 5/12 |
| Multicenter, Japan 2000[61] |
Leukemia/others | 135 | TBI-based | CSP/Tac/MTX/Steroids | 3.2 5.5 4.9 |
0.06(M) 0.09(P) 0.01(M+P) |
Ex vivo CD34+ selection | 13% | II~IV 21% |
35% | 47% | 22%for SR 79%for HR |
5-year 39% for SR 5% for HR |
| Tuebingen, Germany 2004[22] |
AML/ALL/others | 63 | TBI or Bu-based with F/TT/ATG/Cy | Extensive TCD | 19.5 | 0.011 | Ex vivo CD34/CD133 selection | 17% | II 7% | 13% | 28% | 30% | 3-year 48% (ALL/NHL) |
| USC, USA 2004[13] |
AML/ALL | 201 | TBI/VP16/Ara-C/Cy/ATG | Partial TCD CSP, MP, ATG |
1.9 | 0.05 | Ex vivo TCD with T10B9/OKT3 | 2% | 13% | 15% | 51% | 31% | 5-year 18% |
| Multicenter, Canada, 2004[62] |
AML | 11 | Mel/TT/F/ATG | TCD | 13.7 | 0.005 | Ex vivo CD34 selection | 0% | 0% | NA | 55% | 37% | 9-month 9% |
| Perugia, Italy 2005[18,21] |
AML/ALL/CML | 175 | TBI/TT/F/ATG | Extensive TCD | 12.8 | 0.01 | Ex vivo CD34 selection | 6% | II~IV 8% | 4% | 36.5% | 24% for AML 27% for ALL |
5-year 47% in CR 4% in rel |
| Tuebingen, Germany 2007[25] |
HM/AA | 38 | F/TT/Mel/OKT3 | TCD | 16 | 0.049 | CD3/CD19 negative selection | 17% | II~IV 27% | 2.6% | 70% for SR 20% for HR |
||
| Multicenter, Germany 2008[24] |
HM | 29 | F/TT/Mel/OKT3 | TCD | 7.6 | 0.044 | CD3/CD19 negative selection | 0% | II~IV 48% | 3/29 | 8/29 | 41% | 1-year 35% |
| Non-T-cell depleted | |||||||||||||
| Jone-Hopkins University 2004[37] |
Leukemia/MDS | 56 | F/CY/TBI(2 Gy) | Tac/MMF/CY | NA | NA | Not done | 17% | 66% | NR | 9%(d100) | NA | 1-year 38% |
| Beijing, China 2006[11] |
ALL/AML/CML/MDS | 171 | Bu/Ara-C/CY/Me-CCNU/ATG | CSP/MMF/MTX short | 1.8 | 220 | Not done | 0 | 55% | 47% | 2-year 19% for SR 31% for HR |
12% for SR 39% for HR |
2-year 68% for SR 42% for HR |
| Japan, 2006[39] | Leukemia/lymphoma | 26 | F/Bu/ATG | Tac/MP | 6.55 | 254 | In vitro TCD with ATG | 4% | 19% | 25% | 15% (d100) | 3-year 61% | |
| Duke University, USA 2007[38] |
Leukemia/MDS/MPD | 49 | F/CY/Alemtuzumab | MMF ± CSP Partial TCD |
13.5 | 460 | In vivo ± ex vivo TCD/Alemtuzumab | 14% | 16% | 14% | 31% | 49% | 1-year 43% |
*AML = acute myeloid leukemia; ALL = acute lymphoid leukemia; Ara-C = cytarabine; ATG = anti-thymocyte globulin; BU = busulfan; CML = chronic myeloid leukmemia; CR = complete remission; CSP = cyclosporine A; CY = cyclophosphamide; DFS = disease free survival; F = fludarabine; GVHD = graft versus host disease; HM = hematologic malignancies; HR = high risk; MDS = myelodysplastic syndrome; Mel = melphalan; MMF = mycophenolate mofetil; MP = methylprednisolone; MTX = methotrexate; NA = not available; NHL = non-Hodgkin lymphoma; OS = overall survival; pts = patients; rel = relapse; SR = standard risk; Tac = tacrolimus; TBI = total body irradiation; TCD = T-cell depletion; TRM = transplant related motality; TT = thiotepa.